| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.21 | 6e-11 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-08 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.17 | 5e-08 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-07 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-07 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.16 | 3e-07 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.14 | 5e-06 |